Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.0
7.8
Journals
Vaccines
Special Issues
Challenges and Barriers to COVID-19 Vaccination: How to Prove Vaccine...
share announcement

Challenges and Barriers to COVID-19 Vaccination: How to Prove Vaccine Effectiveness

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "COVID-19 Vaccines and Vaccination".

Deadline for manuscript submissions: closed (15 November 2022) | Viewed by 6353

Special Issue Editor

Dr. Marta Fadda

E-Mail Website
Guest Editor
Istituto di salute pubblica (IPH), Facoltà di scienze biomediche, USI - Universita' della Svizzera italiana, Lugano, Switzerland
Interests: vaccine hesitancy; qualitative research; public health; ethics

Special Issue Information

Dear Colleagues, 

As the Omicron variant spreads like wildfire across the globe, new challenges emerge for COVID-19 vaccination uptake. As this new variant appears not to spare vaccinated individuals, the effectiveness of current efforts to reach a high vaccine uptake are threatened. I would like to encourage the presentation to this Special Issue of recent advances in the understanding of the mechanisms affecting the vaccination decision, in light of the spread of new variants of concern. Adding new information on this subject may lead to a better understanding of how the unfolding of the current pandemic may jeopardize current immunization efforts and aid in the design of new communication strategies to sustain and promote vaccine uptake.

Kind regards
Dr. Marta Fadda
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • COVID-19
  • Sars-Cov-2
  • vaccination
  • effectiveness
  • Omicron
  • communication
  • hesitancy

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

13 pages, 1572 KiB  
Article
Global Implications for COVID-19 Vaccine Series Completion: Insights from Real-World Data from the United States
by Jessica K. DeMartino, Ruibin Wang, Cindy Y. Chen, Nina Ahmad, Brahim Bookhart and Laurene Mascola
Vaccines 2022, 10(9), 1561; https://0-doi-org.brum.beds.ac.uk/10.3390/vaccines10091561 - 19 Sep 2022
Viewed by 3094
Abstract
This retrospective cohort analysis leveraged vaccination data for BNT162b2, mRNA-1273, and Ad26.COV2.S in the United States from the Komodo Healthcare Map database, the TriNetX Dataworks USA Network, and Cerner Real-World EHR (electronic health record) Data to evaluate rates of adherence to and completion [...] Read more.
This retrospective cohort analysis leveraged vaccination data for BNT162b2, mRNA-1273, and Ad26.COV2.S in the United States from the Komodo Healthcare Map database, the TriNetX Dataworks USA Network, and Cerner Real-World EHR (electronic health record) Data to evaluate rates of adherence to and completion of COVID-19 vaccination series (November 2020 through June 2021). Individuals were indexed on the date they received the first dose of a COVID-19 vaccine, with an adherence follow-up window of 42 days. Adherence/completion rates were calculated in the overall cohort of each database and by month of initiation and stratified by age, race/ethnicity, and urban/rural status. Overall adherence and completion to 2-dose COVID-19 mRNA vaccine schedules ranged from 79.4% to 87.4% and 81.0% to 89.2%, respectively. In TriNetX and Cerner, mRNA-1273 recipients were generally less adherent compared with BNT162b2 across sociodemographic groups. In Komodo, rates of adherence/completion between mRNA-1273 and BNT162b2 were similar. Adherence/completion were generally lower in younger (<65 years) versus older recipients (≥65 years), particularly for mRNA-1273. No other sociodemographic-based gaps in vaccine adherence/completion were identified. These data demonstrate high but incomplete adherence to/completion of multidose COVID-19 vaccines during initial vaccine rollout in the United States. Multidose schedules may contribute to challenges associated with successful global vaccination. Full article
(This article belongs to the Special Issue Challenges and Barriers to COVID-19 Vaccination: How to Prove Vaccine Effectiveness)
►▼ Show Figures

Figure 1

11 pages, 500 KiB  
Article
COVID-19 Vaccine Effectiveness at a Referral Hospital in Northern Peru: A Retrospective Cohort Study
by Mario J. Valladares-Garrido, Sandra Zeña-Ñañez, C. Ichiro Peralta, Jacqueline B. Puicón-Suárez, Cristian Díaz-Vélez and Virgilio E. Failoc-Rojas
Vaccines 2022, 10(5), 812; https://0-doi-org.brum.beds.ac.uk/10.3390/vaccines10050812 - 20 May 2022
Cited by 5 | Viewed by 2615
Abstract
COVID-19 vaccines have achieved a significant reduction in mortality, yet objective estimates are needed in specific settings. We aimed to determine the effectiveness of COVID-19 vaccination at a referral hospital in Lambayeque, Peru. We conducted a retrospective cohort study from February to September [...] Read more.
COVID-19 vaccines have achieved a significant reduction in mortality, yet objective estimates are needed in specific settings. We aimed to determine the effectiveness of COVID-19 vaccination at a referral hospital in Lambayeque, Peru. We conducted a retrospective cohort study from February to September 2021. We included hospitalized patients with COVID-19, whose data were stored in NotiWeb, a patient data system of the Peruvian Ministry of Health. We applied a propensity score-weighting method according to baseline characteristics of patients, and estimated hazard ratios (HR) using Cox regression models. Of 1553 participants, the average age was 55 years (SD: 16.8), 907 (58%) were male, and 592 (38%) deceased at 28-day follow-up. Before hospital admission, 74 (4.8%) had been immunized with at least one vaccine dose. Effectiveness against death in vaccinated patients was 50% at 90-day follow-up (weighted HR 0.50, 95% CI 0.28–0.89). Our results support the effectiveness of COVID-19 vaccination against death and provide information after early immunization in Peru. Full article
(This article belongs to the Special Issue Challenges and Barriers to COVID-19 Vaccination: How to Prove Vaccine Effectiveness)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop